ARTICLE | Company News

Gensia Inc. sales and marketing update

October 11, 1993 7:00 AM UTC

GNSA signed an exclusive agreement with the pharmaceutical products division of Ohmeda Inc. under which GNSA will distribute and market Brevibloc, an acute care cardiovascular drug, in Europe. Brevibloc is an ultra-short-acting intravenous beta-blocker to treat perioperative tachycardia and hypertension. A secondary indication is the treatment of supraventricular tachycardia in emergency situations.

GNSA will make an undisclosed initial payment to Ohmeda with two additional payments over the next two years in return for exclusive distribution and marketing rights in Europe. GNSA also will pay royalties on sales over a 10-year period. ...